Summary

Liquid Biopsy Market Size, Share, and Analysis, By Product (Services, Kits & Reagents, and Platforms & Instruments), By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytometry, Digital PCR), By Application (Diagnosis and Screening, Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

PRODUCT OVERVIEW
Liquid Biopsy Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15.3% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 5.1 billion and is projected to reach USD 24.7 billion by the completion of 2034.
Liquid biopsy is a non-invasive diagnostic test that identifies disease indicators in bodily fluids, such as blood. It is particularly useful in detecting genetic and molecular alterations, especially in cancer. Unlike traditional biopsies that require surgical procedures to obtain tissue samples, liquid biopsies involve a simple blood test or fluid sample collection, making the process less invasive and more accessible. Liquid biopsy is utilized for early cancer detection, monitoring treatment response, tracking disease progression, and identifying minimal residual disease and relapse. Techniques like Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Digital Droplet PCR are employed to detect and analyze genetic mutations, chromosomal abnormalities, and disease biomarkers. Beyond cancer, liquid biopsy is also used to test for genetic defects in unborn babies, monitor organ transplant rejection, and is becoming applicable in heart, infection-related, and immune system disorders.

MARKET HIGHLIGHTS
Liquid Biopsy Market is expected to reach USD 24.7 billion during the forecast period, driven by the increasing demand for non-invasive diagnostics. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, thus increasing its use for various diagnostic purposes. As global cancer cases continue to rise, there is a growing need for tools that can detect and monitor the disease in its early stages, leading to a higher demand for liquid biopsies. Additionally, advancements in technologies such as PCR, NGS, and Digital Droplet PCR enhance the precision and sensitivity of liquid biopsies, further fueling market growth. New technological advancements are also making liquid biopsies more accurate and affordable, making them more accessible to healthcare providers and patients.
Liquid Biopsy Market Segments:

• By Product
o Services
o Kits & Reagents
o Platforms & Instruments
• By Circulating Biomarker
o Circulating Tumor DNA
o Circulating Tumor Cell
o Extracellular Vesicles
o Others
• By Technology
o Polymerase Chain Reaction (PCR)
o Next-Generation Sequencing (NGS)
o Cytometry
o Digital PCR
• By Application
o Diagnosis and Screening
o Treatment Monitoring
o Prognosis and Recurrence Monitoring
o Treatment Selection

MARKET DYNAMICS
Growth Drivers
Increasing Cancer Incidence is Critical to Boost the Adoption of Liquid Biopsy
Advancements in Technology Will Aid the Market
Restraint
High Costs Can Limit the Growth of the Liquid Biopsy Market

Key Players
• Guardant Health, Inc.
• QIAGEN N.V.
• Natera, Inc.
• Singular Genomics Systems, Inc.
• Exosome Diagnostics, Inc.
• Illumina, Inc.
• Asuragen, Inc.
• MDxHealth SA
• Thermo Fisher Scientific Inc.
• Epigenomics AG
• Sysmex Corporation
• Circulating Cell-Free Genome Atlas (CCGA)
• Foundation Medicine, Inc.
• Biocept, Inc.
• Roche Holding AG
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)


Global Laboratory Temperature Control Units Market is further segmented by region into:
• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA


Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 3-month post-sales analyst support.

ページTOPに戻る

Table of Contents

1.Executive Summary
1.1. Regional Market Share
1.2.Business Trends
1.3. Liquid Biopsy Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1.Market Definition
3.2.Liquid Biopsy Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.Liquid Biopsy Market – Industry Insights
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.Risk Analysis
9. Market Analysis
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.Liquid Biopsy Market
10.1.Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Liquid Biopsy Market Size & Forecast 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Product
11.3.1.1. Services
11.3.1.1.1.By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2.Kits & Reagents
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2.Market Share (%) 2024A-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.3.Platforms & Instruments
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2.Market Share (%) 2024A-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Circulating Biomarker
11.3.2.1.Circulating Tumor DNA
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2.Market Share (%) 2024A-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Circulating Tumor Cell
11.3.2.2.1.By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Extracellular Vesicles
11.3.2.3.1.By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.4. Others
11.3.2.4.1.By Value (USD Million) 2024A-2034F
11.3.2.4.2. Market Share (%) 2024A-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.By Technology
11.3.3.1.Polymerase Chain Reaction (PCR)
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2.Market Share (%) 2024A-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Next-Generation Sequencing (NGS)
11.3.3.2.1.By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Cytometry
11.3.3.3.1.By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Digital PCR
11.3.3.4.1.By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.By Application
11.3.4.1.Diagnosis and Screening
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2.Market Share (%) 2024A-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Treatment Monitoring
11.3.4.2.1.By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.3. Prognosis and Recurrence Monitoring
11.3.4.3.1.By Value (USD Million) 2024A-2034F
11.3.4.3.2. Market Share (%) 2024A-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.4.Treatment Selection
11.3.4.4.1.By Value (USD Million) 2024A-2034F
11.3.4.4.2. Market Share (%) 2024A-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F
12.North America Liquid Biopsy Market Size & Forecast 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Product
12.3.2. By Circulating Biomarker
12.3.3. By Technology
12.3.4. By Application
12.4. Country
12.4.1. United States
12.4.2. Canada
13.Europe Liquid Biopsy Market Size & Forecast 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product
13.3.2. By Circulating Biomarker
13.3.3. By Technology
13.3.4. By Application
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.Asia-Pacific Liquid Biopsy Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product
14.3.2. By Circulating Biomarker
14.3.3. By Technology
14.3.4. By Application
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.Middle East and Africa Liquid Biopsy Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product
15.3.2. By Circulating Biomarker
15.3.3. By Technology
15.3.4. By Application
15.4.Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Liquid Biopsy Market Size & Forecast 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Product
16.3.2. By Circulating Biomarker
16.3.3. By Technology
16.3.4. By Application
16.4. Country
16.4.1.Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Guardant Health, Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.2. QIAGEN N.V.
18.3. Natera, Inc.
18.4. Singular Genomics Systems, Inc.
18.5. Exosome Diagnostics, Inc.
18.6. Illumina, Inc.
18.7. Asuragen, Inc.
18.8. MDxHealth SA
18.9. Thermo Fisher Scientific Inc
18.10.Epigenomics AG
18.11.Sysmex Corporation
18.12. Circulating Cell-Free Genome Atlas (CCGA)
18.13. Foundation Medicine, Inc
18.14.Biocept, Inc.
18.15. Roche Holding AG
18.16. Other Prominent Players
19. Appendix
20.Consultant Recommendation